Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | MITF | O75030 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29695546 | 0.83 | NPC1 (0.62) | MAPTNPC1RAB9AALDH1A1LMNA | |
| SCHEMBL29744982 | 0.82 | MEN1 (0.71) | MAPTNPC1RAB9AALDH1A1LMNA | |
| SCHEMBL2177925 | 0.82 | MAPT (0.69) | MAPTNPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL4810409 | 0.82 | MEN1 (0.71) | MAPTNPC1RAB9AALDH1A1LMNA | |
| SCHEMBL4892092 | 0.82 | MAPT (0.55) | MAPTNPC1RAB9AALDH1A1LMNA | |
| SCHEMBL11714010 | 0.81 | MEN1 (0.69) | MAPTNPC1RAB9AALDH1A1LMNA | |
| SCHEMBL11554972 | 0.81 | GRM5 (0.58) | MAPTNPC1RAB9AMEN1KMT2A | |
| SCHEMBL3628262 | 0.80 | MEN1 (0.51) | MAPTNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL4896581 | 0.80 | KDM4E (0.52) | MAPTNPC1RAB9AALDH1A1LMNA | |
| SCHEMBL11016312 | 0.79 | MEN1 (0.63) | MAPTNPC1RAB9AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4195088-A | ANTISECRETORY AGENTS, ANTIULCER AGENTS, ANOREXIGENIC AGENTS | ROUSSEL UCLAF (FR) | 1980-03-25 | — | — | US | claimed |
| EP-0006931-A1 | NEW SUBSTITUTED BY-PRODUCTS OF 1,3-DIHYDRO IMIDAZO (4,5-b) PYRIDIN-2-ONE, PROCESS, APPLICATION, COMPOSITIONS AND INTERMEDIATE COMPOUNDS OBTAINED | ROUSSEL-UCLAF (FR) | 1980-01-23 | — | — | EP | claimed |
| WO-1979000206-A1 | NEW SUBSTITUTED BY-PRODUCTS OF 1,3-DIHYDRO IMIDAZO(4,5-B)PYRIDIN-2-ONE,PROCESS,APPLICATION,COMPOSITIONS AND INTERMEDIATE COMPOUNDS OBTAINED | ROUSSEL UCLAF (FR) | 1979-04-19 | — | — | WO | claimed |
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| EP-2673269-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012107465-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | WO | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-6727245-B2 | 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-27 | — | — | US | disclosed |
| EP-0770079-B1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| CN-1051548-C | Heterobicyclic derivatives, pharmaceutical compositions containing them, process for preparing them and their use | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-04-19 | — | — | CN | disclosed |
| CN-1250776-A | Heterodicyclic compound derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-04-19 | — | — | CN | disclosed |
| EP-0920867-A1 | Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-06-09 | — | — | EP | disclosed |
| CN-1157617-A | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-08-20 | — | — | CN | disclosed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
| US-4195088-A | ANTISECRETORY AGENTS, ANTIULCER AGENTS, ANOREXIGENIC AGENTS | ROUSSEL UCLAF (FR) | 1980-03-25 | — | — | US | disclosed |
| EP-0006931-A1 | NEW SUBSTITUTED BY-PRODUCTS OF 1,3-DIHYDRO IMIDAZO (4,5-b) PYRIDIN-2-ONE, PROCESS, APPLICATION, COMPOSITIONS AND INTERMEDIATE COMPOUNDS OBTAINED | ROUSSEL-UCLAF (FR) | 1980-01-23 | — | — | EP | disclosed |
| WO-1979000206-A1 | NEW SUBSTITUTED BY-PRODUCTS OF 1,3-DIHYDRO IMIDAZO(4,5-B)PYRIDIN-2-ONE,PROCESS,APPLICATION,COMPOSITIONS AND INTERMEDIATE COMPOUNDS OBTAINED | ROUSSEL UCLAF (FR) | 1979-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, AKT3 | MAPT 1752/4885NPC1 941/4885RAB9A 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.